Cerevel Therapeutics Holdings, Inc.
CERE evidence brief
What we can confirm
- BioSniper Score:
- 8.5 / 10
- Lead Asset:
- cvl-871 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for CERE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
cvl-871 (Phase 2)
Next Catalyst
—
Tracking 5 pipeline candidates · 2 clinical trials for Cerevel Therapeutics Holdings, Inc..
Run Cerevel Therapeutics Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cerevel Therapeutics Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Cerevel Therapeutics Holdings, Inc.'s lead drug candidate?
Cerevel Therapeutics Holdings, Inc.'s most advanced tracked candidate is cvl-871 (Phase 2) for dementia-related apathy.
Who is the CEO of Cerevel Therapeutics Holdings, Inc.?
Anthony Coles, M.D. is the chief executive officer of Cerevel Therapeutics Holdings, Inc. (CERE).
What therapeutic areas does Cerevel Therapeutics Holdings, Inc. focus on?
Cerevel Therapeutics Holdings, Inc. develops therapies across Oncology, Neurology, Hematology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.